



# Relationship between calcium release and NADPH oxidase inhibition in human neutrophils

Michael D. Salmon, Jatinder Ahluwalia \*

Leukocyte and Ion Channel Research Laboratory, School of Health and Biosciences, University of East London, Stratford Campus, London E15 4LZ, UK

## ARTICLE INFO

### Article history:

Received 10 April 2009

Available online 23 April 2009

### Keywords:

*N*-formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP)

Platelet activating factor (PAF)

Leukotriene B<sub>4</sub> (LTB<sub>4</sub>)

Depolarisation

Calcium release

Neutrophils

NADPH oxidase

## ABSTRACT

The aim of this study was to investigate the possible relationship between NADPH oxidase activity and changes in cytosolic Ca<sup>2+</sup> in response to different agonists. Treatment of neutrophils with leukotriene B<sub>4</sub> (LTB<sub>4</sub>) demonstrated characteristic changes to cytosolic Ca<sup>2+</sup> yielding an EC<sub>50</sub> of 4 nM. The pA<sub>2</sub> values for the specific LTB<sub>4</sub> receptor (BLT) antagonists, U-75302 and LY-255283 were 6.32 and 6.38, respectively. Similarly, neutrophils treated with *N*-formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP) and platelet activating factor (PAF) exhibited changes in cytosolic Ca<sup>2+</sup> in a dose dependant manner with pD<sub>2</sub> values of 9.0 and 9.9, respectively. The phorbol ester PMA prevented elevations in cytosolic Ca<sup>2+</sup> in response to LTB<sub>4</sub>, FMLP and PAF with IC<sub>50</sub> values of 5.88, 1.44 and 5.71 nM, respectively. In addition, potent NADPH oxidase inhibitors apocynin and diphenyleneiodonium (DPI) inhibited FMLP mediated cytosolic Ca<sup>2+</sup> release. These results demonstrate that inhibition of the NADPH oxidase suppresses cytosolic Ca<sup>2+</sup> release in FMLP activated human neutrophils.

© 2009 Elsevier Inc. All rights reserved.

## Introduction

Polymorphonuclear neutrophils form a critically important component of the body's initial innate immune response and are implicated in several inflammatory processes. The NADPH oxidase is a key driving force in powering the microbicidal capacity of these cells. Mutations in any component of the NADPH oxidase prevent the effective functioning of the neutrophil, resulting in chronic granulomatous disease (CGD), which if not treated results in susceptibility to fatal infections [1]. Normal functioning of neutrophils therefore relies upon the concerted action between the NADPH oxidase and different ion channels, which enables neutrophils to prodigiously fulfil their important role when recruited to sites of inflammation or infection. At these sites, neutrophils can endogenously generate inflammatory mediators. One of these is the potent pro-inflammatory bioactive eicosanoid derived from arachidonate known as leukotriene B<sub>4</sub> (LTB<sub>4</sub>) [2].

Initially discovered in 1979 [3], LTB<sub>4</sub> has been implicated in the activation of several cellular functions. The most significant being the involvement of LTB<sub>4</sub> in the activation of several granulocyte responses. Neutrophils have been shown to exhibit a multitude of effects in response to LTB<sub>4</sub>, some of which include activating neutrophil chemotaxis [4] and secretion of granule enzymes [5].

In addition to LTB<sub>4</sub>, specific neutrophil responses can be stimulated by the potent chemo-attractant *N*-formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP) and platelet activating factor (PAF). Binding of LTB<sub>4</sub>, PAF or FMLP to receptors on the neutrophil plasma membrane releases intracellular calcium ([Ca<sup>2+</sup>]<sub>i</sub>) via the phospholipase-inositol triphosphate pathway. This depletion of [Ca<sup>2+</sup>]<sub>i</sub> in turn leads to Ca<sup>2+</sup> influx via store operated channels [6] resulting in elevated Ca<sup>2+</sup> levels that are thought to be implicated in several Ca<sup>2+</sup> dependant pro-inflammatory responses.

In neutrophils, refilling of these stores via store operated channels, a phenomenon known as capacitative Ca<sup>2+</sup> entry, is mediated by the NADPH oxidase [6]. An important feature of the neutrophil NADPH oxidase is that it generates an electron current [7,8] which depolarise the membrane. This electron current depolarises the plasma membrane at a rate of 2.3 V s<sup>-1</sup> if there was no counterion to oppose the membrane depolarisation [7]. Under current clamp conditions proton fluxes thorough voltage-gated proton channels [7] and/or chloride flux via tamoxifen insensitive swell activated chloride channels can oppose the extreme membrane depolarisation generated by the NADPH oxidase [9,10]. The electrogenic characteristic of the NADPH oxidase means that its inhibition will also abrogate membrane depolarisation [7] and augments Ca<sup>2+</sup> entry into the cell [11]. Depolarisation thereby alters the electrochemical gradient across the neutrophil plasma membrane and limits Ca<sup>2+</sup> entry into the cell. Taken together, these findings are thought to suggest that the NADPH oxidase puts a protective restraint on Ca<sup>2+</sup> entering into the neutrophil.

\* Corresponding author.

E-mail address: [j.ahluwalia@uel.ac.uk](mailto:j.ahluwalia@uel.ac.uk) (J. Ahluwalia).

The role of LTB<sub>4</sub>, PAF and FMLP in initiating and modulating various neutrophil responses has been under examination by several groups in recent years, however, very little data exists in human neutrophils that investigates to what extent the mobilisation of calcium release in response to these agonists is mediated by the NADPH oxidase. This work was pursued because it would be important to understand the effect NADPH oxidase inhibitors on changes in [Ca<sup>2+</sup>]<sub>i</sub> release in response to different agonists. The objectives in the current paper were 2-fold. First, to provide a detailed spectrofluorometric analysis which examines the changes in [Ca<sup>2+</sup>]<sub>i</sub> release in response to LTB<sub>4</sub>, PAF and FMLP. Second, to investigate the role of the NADPH oxidase in modulating changes in [Ca<sup>2+</sup>]<sub>i</sub> release in response to FMLP in activated human neutrophils.

## Materials and methods

**Materials.** Leukotriene B<sub>4</sub> (LTB<sub>4</sub>) was purchased from Tocris (UK) at a ready made stock concentration of 50 µg/ml. Platelet activating factor (C16 PAF) and LY-255283 were purchased from Tocris (UK) and made to stock concentrations of 5 mM (water) and 25 mM (DMSO), respectively. U-75302 was purchased from Biomol (UK) and made up to a stock concentration of 1 mM in DMSO. FURA-2AM was purchased from Invitrogen (UK) as a ready made 1 mM solution. Unless otherwise indicated, all other reagents were purchased from Sigma, Chemicals, UK. A stock concentration of phorbol 12-myristate 13-acetate (PMA, 1 mg/ml), *N*-formyl-L-methionyl-L-leucyl-L-phenylalanine (FMLP, 10 mM), apocynin (100 mM) and diphenyleneiodonium chloride (DPI, 10 mM) were made up in DMSO.

**Neutrophil isolation.** Human neutrophils were isolated from heparin anti-coagulated venous blood as described [7] from healthy consenting adults according to the appropriate ethical guidelines at University of East London. Purified neutrophils were re-suspended in Dulbecco's PBS (D-PBS, Sigma, UK) pH 7.2 prior to use.

**Calcium dye loading.** FURA-2AM was used as the fluorescent Ca<sup>2+</sup> sensitive indicator for these experiments [12]. Neutrophils were loaded with FURA-2AM (2 µM, final) by sedimenting for 2 min at 2000 rpm in a microcentrifuge followed by re-suspension in D-PBS containing 1 mM CaCl<sub>2</sub>. After incubation at 37 °C for 30 min in the dark, neutrophils were washed twice in Ca<sup>2+</sup> free D-PBS and stored at room temperature and protected from light.

**Spectrofluorimetric measurement of Ca<sup>2+</sup> fluxes.** Intracellular [Ca<sup>2+</sup>]<sub>i</sub> was monitored by spectrofluorimetry by the ratiometric method as described [12] and was adapted for use in a micro-titre spectrofluorimetric 96 well plate reader (Thermo Labsystems Fluoroskan Ascent FL Fluorescence microplate reader). Ninety microliters of neutrophil suspension (2 × 10<sup>7</sup>/ml) were added to each well of a flat-bottomed black 96 well micro-titre plate. This was followed by 10 µl of each addition of agonist and/or inhibitor and orbital shaking for 5 s at 1200 rpm. The micro-titre plate reader was programmed to pre-incubate neutrophils at 37 °C for 3 min to obtain a stable base-line before the first addition of agonist and/or inhibitor was made using an automatic multi-channel pipette. Changes in FURA-2AM fluorescence were monitored at 340 and 380 nm excitation wavelengths and 510 nm emission, with a time between reading at each wavelength of 3.4 s. Each reading was integrated for 20 ms and a plate acceleration of 10 ms was used, and the time between reading adjacent wells was 50 ms. The time between two readings of a block of wells (typically 12 wells) at both wavelengths was 8.1 s. Alterations in fluorescence intensity were then monitored over a 3–12 min period. The final volume in each well was 100 µl containing a total of 1.8 × 10<sup>6</sup> neutrophils. Calibration at the end of an experiment was performed by lysing cells by the addition of 0.1% Triton X-100 and 1 mM CaCl<sub>2</sub> to

determine  $F_{340\text{ nm}}/F_{380\text{ nm}} = R_{\text{max}}$ .  $R_{\text{min}}$  was determined by the subsequent addition of 25 mM EGTA. Intracellular [Ca<sup>2+</sup>]<sub>i</sub> was calculated using the formula [12]:  $[Ca^{2+}]_i = K_d \{ (R - R_{\text{min}}) / (R_{\text{max}} - R) \} \cdot \{ S_{F2} / S_{b2} \}$ ,  $S_{F2}$  is the fluorescence of free FURA-2AM at 380 nm, determined in the presence of 25 mM EGTA and  $S_{b2}$  is the fluorescence at 380 nm of FURA-2AM saturated with Ca<sup>2+</sup> measured in the presence of 1 mM Ca<sup>2+</sup> in cells lysed with Triton X-100. The  $K_d$  of FURA-2AM was taken to be 224 nM at 37 °C [12].

**Data analysis.** Statistical data was analysed using the one-way ANOVA Bonferroni test of multiple comparisons on Graph Pad Prism 4.0 software.

## Results

### *Effect of BLT receptor antagonists on [Ca<sup>2+</sup>]<sub>i</sub> mobilisation in response to LTB<sub>4</sub> in human neutrophils*

Pre-treatment of neutrophils loaded with FURA-2AM with LTB<sub>4</sub> (20 nM) evoked an sharp increase in [Ca<sup>2+</sup>]<sub>i</sub> from a basal value of approximately 100 nM to a peak of 753 nM ± 12 ( $n = 3$ ). After the initial transient peak, [Ca<sup>2+</sup>]<sub>i</sub> declined rapidly to basal values (Fig. 1A). The EC<sub>50</sub> of the LTB<sub>4</sub> induced responses was 4.02 nM (Fig. 1B). The effect of BLT receptor antagonists on [Ca<sup>2+</sup>]<sub>i</sub> responses induced by LTB<sub>4</sub> were studied using antagonists U-75302 and LY-255283 (Fig. 1B). The respective pA<sub>2</sub> values were 6.32 and 6.38, respectively, estimated using the Gaddum equation;  $pA_2 = \log(\text{concentration ratio}) - \log[\text{antagonist}]$  assuming competitive antagonism.

### *Effect of FMLP and PAF on [Ca<sup>2+</sup>]<sub>i</sub> mobilisation in human neutrophils*


Neutrophils treated with FMLP evoked a rapid increase in [Ca<sup>2+</sup>]<sub>i</sub> from resting values of about 100 nM and rapidly rising to peak values in excess of 700 nM (Fig. 2A). After the initial elevation there was a decrease of [Ca<sup>2+</sup>]<sub>i</sub> to basal levels that took longer in comparison to LTB<sub>4</sub>. The EC<sub>50</sub> of the FMLP induced response was 0.11 nM ( $pD_2 = 9.96 \pm 0.09$ ,  $n = 3$ ) (Fig. 2B). Similarly, PAF resulted in a sharp increase in [Ca<sup>2+</sup>]<sub>i</sub> from resting values of 80 nM to a peak in excess of 500 nM (Fig. 2C). After the initial peak in response to PAF, [Ca<sup>2+</sup>]<sub>i</sub> mobilisation took longer to return to steady-state values when compared to FMLP. The EC<sub>50</sub> value of PAF mediated [Ca<sup>2+</sup>]<sub>i</sub> was 0.87 nM ( $pD_2 = 9.05 \pm 0.24$ ,  $n = 4$ ) (Fig. 2D).

### *Inhibition by PMA of [Ca<sup>2+</sup>]<sub>i</sub> release in response to LTB<sub>4</sub>, PAF and FMLP in human neutrophils*


The phorbol ester PMA potently inhibited in a dose dependent manner [Ca<sup>2+</sup>]<sub>i</sub> elevations in response to LTB<sub>4</sub> (Fig. 3A), FMLP (Fig. 3B) and PAF (Fig. 3C), with IC<sub>50</sub> values of 5.88, 1.44 and 5.71 nM respectively. Using the Cheng–Prussoff relationship [13],  $K_i$  values for inhibition of FMLP, LTB<sub>4</sub> and PAF were  $1.33 \times 10^{-10}$  M,  $1.34 \times 10^{-10}$  M and  $2.53 \times 10^{-9}$  M, respectively.

### *NADPH oxidase inhibition suppresses [Ca<sup>2+</sup>]<sub>i</sub> release in FMLP stimulated human neutrophils*

Experiments were carried out on neutrophils incubated with the potent NADPH oxidase inhibitors DPI [14] and apocynin [15] prior to stimulation of [Ca<sup>2+</sup>]<sub>i</sub> responses with FMLP. Apocynin significantly inhibited FMLP stimulated [Ca<sup>2+</sup>]<sub>i</sub> release (Fig. 4A) with an IC<sub>50</sub> of 21 µM (Fig. 4B). Similarly, in the presence of DPI, neutrophils that had been stimulated using FMLP, demonstrated significantly reduced levels of [Ca<sup>2+</sup>]<sub>i</sub> release in comparison to untreated cells (Fig. 4C). DPI inhibited [Ca<sup>2+</sup>]<sub>i</sub> release from peak values from 568 nM ± 83 ( $n = 3$ ) to 141 nM ± 18 ( $n = 3$ ) (Fig. 4D).



**Fig. 1.** Dependence of  $[Ca^{2+}]_i$  responses with LTB<sub>4</sub> in human neutrophils in the absence and presence of BLT receptor antagonists. Transient peak in response to 20 nM LTB<sub>4</sub> ( $n = 3$ ) (A). BLT receptor antagonist dose response curves in response to LTB<sub>4</sub> ( $n = 3$ ) (B). Error bars show the  $\pm$ SEM.




**Fig. 2.** Dependence of  $[Ca^{2+}]_i$  on FMLP and PAF responses in human neutrophils. Time course of changes in  $[Ca^{2+}]_i$  in response to 10 nM FMLP (A) and the concentration dependence curve of  $[Ca^{2+}]_i$  to FMLP ( $n = 3$ ) (B). Time course of changes in  $[Ca^{2+}]_i$  in response to 100 nM PAF (C) and the concentration dependence curve of  $[Ca^{2+}]_i$  to PAF ( $n = 4$ ) (D). Error bars show the  $\pm$ SEM.

## Discussion


Very little has been documented on the effect of NADPH oxidase activity on agonist induced calcium release. This is in part due to the practical time constraints of conventional fluorimetric techniques. In this report, the development of a method of intracellular  $[Ca^{2+}]$  measurement using a microtitre plate fluorimetric reader capable of ratiometric kinetic measurements has allowed more extensive and detailed analysis. Using this method, the results of the current study has revealed novel features of the inter-relationships between mechanisms of calcium release in human neutrophils stimulated by pro-inflammatory lipid mediators (LTB<sub>4</sub> and

PAF) and the chemotactic peptide FMLP. In this study we have shown for the first time that potent inhibitors of the NADPH oxidase can suppress FMLP mediated  $[Ca^{2+}]_i$  release in human neutrophils.

In addition, our study provides extensive analysis of LTB<sub>4</sub> induced  $[Ca^{2+}]_i$  release in human neutrophils. Previously, there has been a lack of Schild analysis in identifying receptor mechanisms that mediate the effect of LTB<sub>4</sub> induced  $[Ca^{2+}]_i$  changes in human neutrophils. Similar apparent affinity values ( $pA_2$ ) have been infrequently calculated for BLT receptors in neutrophils. The action of LTB<sub>4</sub> is mediated by two G-protein receptors. Of these receptors BLT1 is only activated by LTB<sub>4</sub> whereas BLT2 can be activated by



**Fig. 3.** Effect of PMA on changes in cytosolic calcium in response to LTB<sub>4</sub>, FMLP and PAF in activated human neutrophils. PMA inhibited [Ca<sup>2+</sup>]<sub>i</sub> release in LTB<sub>4</sub> (A), FMLP (B) and PAF (C) stimulated neutrophils. Cells were pre-incubated for 3 min and PMA was added at time zero. Three minutes later, 0.5 nM LTB<sub>4</sub> ((A) *n* = 3), 1 nM FMLP ((B) *n* = 3) or 1 nM PAF ((C) *n* = 3) were added. The maximum [Ca<sup>2+</sup>]<sub>i</sub> recorded after addition of agonist are plotted. The error bars show  $\pm$ SEM.



**Fig. 4.** Inhibition by DPI and apocynin of calcium release in response to 1 nM FMLP. Neutrophils were pre-incubated at 37 °C and the indicated concentration of apocynin added at zero time and FMLP was added as indicated by the arrow in the absence of calcium (A). (B) The concentration dependence of inhibition of basal and peak [Ca<sup>2+</sup>]<sub>i</sub> by apocynin. The IC<sub>50</sub> of apocynin was 21  $\mu$ M. (C) The time courses of [Ca<sup>2+</sup>]<sub>i</sub> in response to 1 nM FMLP (*n* = 3) with DPI (5  $\mu$ M) added as indicated by the arrow in the absence of calcium. The corresponding peak changes in [Ca<sup>2+</sup>]<sub>i</sub> recorded (peak-basal) in the absence and presence of DPI (5  $\mu$ M) with 1 nM FMLP (D). Error bars indicate  $\pm$ SEM (*n* = 3).

not only LTB<sub>4</sub> but also by other hydroxyeicosotetraenoic acids [16]. In this study we used two antagonists of the BLT receptors; U-75302 a BLT antagonist that is specific for the high affinity BLT1 receptor and LY-255283, which is specific for the low affinity BLT2 receptor [17]. Both of these antagonists inhibited the binding of LTB<sub>4</sub> to its receptor in a dose dependant manner (Fig. 1B). We found that Schild–Gaddum analysis of these antagonists yielded similar pA<sub>2</sub> values of approximately 6.3 supporting the idea that both antagonists bind to similar sites on the BLT receptor to antagonise the calcium mediated release in human neutrophils. From

the present data we cannot conclude if the LTB<sub>4</sub> mediated responses in neutrophils are mediated by a particular type of BLT receptor. There is growing evidence that BLT1 and BLT2 may function as heterodimers, which would suggest that both of these selective antagonists could inhibit calcium mediated responses in neutrophils, even at concentrations where they inhibit LTB<sub>4</sub> binding specifically to BLT1 or BLT2.

In the current study, activation of neutrophils with LTB<sub>4</sub> (20 nM), FMLP (10 nM) and PAF (100 nM) resulted in the characteristic immediate increase in [Ca<sup>2+</sup>]<sub>i</sub>. The peak concentration of

$[Ca^{2+}]_i$  in LTB<sub>4</sub> stimulated neutrophils was very short lived (60 s, Fig. 1A) in comparison to FMLP treated cells, which took longer to reach basal levels (Fig. 2A). The prolongation of the peak  $[Ca^{2+}]_i$  to reach basal levels in FMLP stimulated cells probably reflects a delayed extrusion of  $[Ca^{2+}]_i$  from intracellular stores in comparison to  $[Ca^{2+}]_i$  responses with LTB<sub>4</sub>. This prolongation of  $[Ca^{2+}]_i$  to return to basal values was the most notable with neutrophils stimulated with PAF in which a much broader response was observed that took much longer to reach basal levels (Fig. 2C). This biphasic component in response to PAF is in agreement with a previous study [18] and has been attributed to the secondary production of LTB<sub>4</sub> after PAF stimulation.

In rabbit neutrophils it has been established that PMA activates the NADPH oxidase and causes membrane depolarization with no apparent rise in  $[Ca^{2+}]_i$  [19]. In addition, in a more recent study it was shown that phorbol esters potentially inhibit divalent cation influx (PMA IC<sub>50</sub> ~50 pM) at concentrations lower than required for stimulation of delayed superoxide formation [20]. The results in the present study are in agreement with these previous studies. In addition, the binding affinity values of PMA were very similar for all the agonists. Our findings show that PMA inhibits  $[Ca^{2+}]_i$  release in neutrophils stimulated with FMLP. Previously, it was shown that PMA only partially inhibited  $[Ca^{2+}]_i$  release in response to 10 nM FMLP [21]. In the present study we demonstrate that PMA at concentrations greater than 1 nM completely inhibited  $[Ca^{2+}]_i$  release in response to FMLP at concentrations of 10-fold less than that was observed in the previous study [21].

Our data show that the NADPH oxidase inhibitors DPI and apocynin can suppress  $[Ca^{2+}]_i$  release in human neutrophils stimulated with FMLP. An interesting variation of our current results is the ability of NADPH oxidase inhibitors to suppress  $[Ca^{2+}]_i$  release. Neutrophils treated with these inhibitors mimic the CGD phenotype and CGD cells are proposed to have higher levels of  $[Ca^{2+}]_i$  influx [11,22]. In one study it was shown that CGD cells stimulated with FMLP had higher levels of cytosolic calcium in comparison to healthy cells and therefore led to the proposal that CGD neutrophils are prone to calcium overload [11]. In contrast, our findings demonstrate that DPI and apocynin treated neutrophils had significantly lower  $[Ca^{2+}]_i$  release levels than untreated cells. The proposed theory of the NADPH oxidase in preventing Ca<sup>2+</sup> overload [11,22] needs to be treated with caution. A previous report using Quin-2 to measure changes in  $[Ca^{2+}]_i$  release from patients with CGD [23] demonstrated that  $[Ca^{2+}]_i$  changes induced by FMLP in CGD cells, were quantitatively and kinetically similar to those observed in normal cells suggesting that a functional oxidase was not responsible for preventing  $[Ca^{2+}]_i$  overload. This finding along with the data presented in the current study therefore casts some uncertainty on the theory proposed by other studies [11,22]. Taken together these findings suggest that the role for a functional NADPH oxidase in preventing Ca<sup>2+</sup> overload in FMLP stimulated human neutrophils is not as clear as was previously thought. For the purposes of the present study we have predominantly focussed on the direct affect of specific NADPH oxidase inhibitors on FMLP induced changes in  $[Ca^{2+}]_i$  release in human neutrophils. FMLP is considered to be the gold standard for investigating different responses in human neutrophils and in addition our study shows that LTB<sub>4</sub> and PAF can increase  $[Ca^{2+}]_i$ . Investigating the direct interaction of NADPH oxidase inhibitors on LTB<sub>4</sub> and PAF induced changes in  $[Ca^{2+}]_i$  release is not the purpose of the present study but no doubt would be an important avenue to explore in future studies.

What do our current findings suggest for the neutrophil NADPH oxidase and changes in  $[Ca^{2+}]_i$  release? A possible interpretation of the current findings could be linked to the role of membrane potential in regulating G-protein coupled receptors. It has been documented that FMLP receptors are dependent on G<sub>i</sub>, whereas both LTB<sub>4</sub> receptor and PAF receptors utilise both G<sub>i</sub> and pertussis toxin

insensitive G-proteins [24]. In addition, membrane potential is thought to have an important role in regulating G-protein coupled receptors in several cell types [25]. Although this has not yet been documented in neutrophils, findings from another non-excitable cell; the megakaryocyte have demonstrated that membrane depolarisation can modulate Ca<sup>2+</sup> mobilisation evoked by G-protein coupled receptors [26]. It is possible in neutrophils that after activation of the NADPH oxidase, concomitant membrane depolarisation may differentially regulate the activities of G-proteins coupled to FMLP receptors and therefore modulate the  $[Ca^{2+}]_i$  release. In the presence of NADPH oxidase inhibitors, membrane depolarisation would be abrogated [7] and therefore, would effect how different G-protein coupled receptors modulate the way  $[Ca^{2+}]_i$  is released from stores in response to different agonists.

In conclusion, our study demonstrates that inhibition of the NADPH oxidase can suppress  $[Ca^{2+}]_i$  release in response to FMLP in human neutrophils and suggests a complex interaction occurs between FMLP receptors and the NADPH oxidase in activated human neutrophils.

## Acknowledgments

We thank Nicholas Seeley and Kevin Clough for their technical assistance.

## References

- [1] D. Goldblatt, A.J. Thrasher, Chronic granulomatous disease, *Clin. Exp. Immunol.* 122 (2000) 1–9.
- [2] A.W. Ford-Hutchinson, M.A. Bray, M.V. Doig, M.E. Shipley, M.J. Smith, Leukotriene B<sub>4</sub>, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes, *Nature* 286 (1980) 264–265.
- [3] P. Borgeat, B. Samuelsson, Transformation of arachidonic acid by rabbit polymorphonuclear leukocytes. Formation of a novel dihydroxyicosatetraenoic acid, *J. Biol. Chem.* 254 (1979) 2643–2646.
- [4] J. Palmblad, C.L. Malmsten, A.M. Udén, O. Rådmark, L. Engstedt, B. Samuelsson, Leukotriene B<sub>4</sub> is a potent and stereospecific stimulator of neutrophil chemotaxis and adherence, *Blood* 58 (1981) 658–661.
- [5] I. Häfström, J. Palmblad, C.L. Malmsten, O. Rådmark, B. Samuelsson, Leukotriene B<sub>4</sub>-a stereospecific stimulator for release of lysosomal enzymes from neutrophils, *FEBS Lett.* 130 (1981) 146–148.
- [6] M. Geiszt, A. Kapus, K. Németh, L. Farkas, E. Ligeti, Regulation of capacitative Ca<sup>2+</sup> influx in human neutrophil granulocytes. Alterations in chronic granulomatous disease, *J. Biol. Chem.* 272 (1997) 26471–26478.
- [7] J. Ahluwalia, Characterisation of electron currents generated by the human neutrophil NADPH oxidase, *Biochem. Biophys. Res. Commun.* 368 (2008) 656–661.
- [8] T.E. DeCoursey, V.V. Cherny, W. Zhou, L.L. Thomas, Simultaneous activation of NADPH oxidase-related proton and electron currents in human neutrophils, *Proc. Natl. Acad. Sci. USA* 97 (2000) 6885–6889.
- [9] J. Ahluwalia, Chloride channels activated by swell can regulate the NADPH oxidase generated membrane depolarisation in activated human neutrophils, *Biochem. Biophys. Res. Commun.* 365 (2008) 328–333.
- [10] J. Ahluwalia, Tamoxifen does not inhibit the swell activated chloride channel in human neutrophils during the respiratory burst, *Biochem. Biophys. Res. Commun.* 375 (2008) 596–601.
- [11] B.K. Rada, M. Geiszt, R. Van Bruggen, K. Nemet, D. Roos, E. Ligeti, Calcium signalling is altered in myeloid cells with a deficiency in NADPH oxidase activity, *Clin. Exp. Immunol.* 132 (2003) 53–60.
- [12] G. Grynkiewicz, M. Poenie, R.Y. Tsien, A new generation of Ca<sup>2+</sup> indicators with greatly improved fluorescence properties, *J. Biol. Chem.* 260 (1985) 3440–3450.
- [13] D.A. Craig, The Cheng–Prusoff relationship: something lost in the translation, *Trends Pharmacol. Sci.* 14 (1993) 89–91.
- [14] A.R. Cross, O.T. Jones, The effect of the inhibitor diphenylene iodonium on the superoxide-generating system of neutrophils. Specific labelling of a component polypeptide of the oxidase, *Biochem. J.* 237 (1986) 111–116.
- [15] J.M. Simons, B.A. 't Hart, Ip Vai Ching, TRAM, H. Van Dijk, R.P. Labadie, Metabolic activation of natural phenols into selective oxidative burst agonists by activated human neutrophils, *Free Radical Biology and Medicine* 3 (1986) 251–258.
- [16] T. Yokomizo, K. Kato, K. Terawaki, T. Izumi, T. Shimizu, A second leukotriene B<sub>4</sub> receptor, BLT2. A new therapeutic target in inflammation and immunological disorders, *J. Exp. Med.* 192 (2000) 421–432.
- [17] A.M. Tager, A.D. Luster, BLT1 and BLT2: the leukotriene B<sub>4</sub> receptors, *Prostaglandins, Leukotrienes and Essential Fatty acids* 69 (2003) 123–134.
- [18] J.J. Rediske, J.C. Quintavalla, W.O. Haston, M.M. Morrissey, B. Seligman, Platelet activating factor stimulates intracellular calcium transients in human



- neutrophils: involvement of endogenous 5-lipoxygenase products, *J. Leukocyte Biol.* 51 (1992) 484–489.
- [19] R.I. Sha'afi, J.R. White, T.F. Molski, J. Shefcyk, M. Volpi, P.H. Naccache, M.B. Feinstein, Phorbol 12-myristate 13-acetate activates rabbit neutrophils without an apparent rise in the level of intracellular free calcium, *Biochem. Biophys. Res. Commun.* 114 (1983) 638–645.
- [20] J.E. Merritt, K.E. Moors, A.T. Evans, P. Sharma, F.J. Evans, C.H. MacPhee, Involvement of calcium in modulation of neutrophil function by phorbol esters that activate protein kinase C isotypes and related enzymes, *Biochem. J.* 289 (1993) 919–926.
- [21] S.A. McCarthy, T.J. Hallam, J.E. Merritt, Activation of protein kinase C in human neutrophils attenuates agonist-stimulated rises in cytosolic free  $\text{Ca}^{2+}$  concentration by inhibiting bivalent-cation influx and intracellular  $\text{Ca}^{2+}$  release in addition to stimulating  $\text{Ca}^{2+}$  efflux, *Biochem. J.* 264 (1989) 357–364.
- [22] G.R. Tintinger, A.J. Theron, H.C. Steel, R. Anderson, Accelerated calcium influx and hyperactivation of neutrophils in chronic granulomatous disease, *Clin. Exp. Immunol.* 123 (2001) 254–632.
- [23] P.D. Lew, C. Wollheim, R.A. Seger, T. Pozzan, Cytosolic free calcium changes induced by chemotactic peptide in neutrophils from patients with chronic granulomatous disease, *Blood* 63 (1984) 231–233.
- [24] B. Haribabu, D.V. Zhelev, B.C. Pridgen, R.M. Richardson, H. Ali, R. Snyderman, Chemoattractant receptors activate distinct pathways for chemotaxis and secretion. Role of G-protein usage, *J. Biol. Chem.* 274 (1999) 37087–37092.
- [25] M.P. Mahaut-Smith, J. Martinez-Pinna, I.S. Gurung, A role for membrane potential in regulating GPCRs?, *Trends Pharmacol Sci.* 29 (2008) 421–429.
- [26] M.P. Mahaut-Smith, J.F. Hussain, M.J. Mason, Depolarization-evoked  $\text{Ca}^{2+}$  release in a non-excitable cell, the rat megakaryocyte, *J. Physiol.* 515 (1999) 385–390.